Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan · Delayed Price · Currency is TWD 72.20
+0.40 (0.56%)
May 29, 2026, 1:30 PM CST
Gongwin Biopharm Holdings Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -142.02 | -114.13 | -82.55 | -92.04 | -292.13 | -121.58 |
Depreciation & Amortization | 9.32 | 11.72 | 11.59 | 13.33 | 13.39 | 12.96 |
Loss (Gain) From Sale of Assets | 0.08 | 0.08 | 0 | - | - | - |
Loss (Gain) From Sale of Investments | -19.21 | -19.21 | -11.11 | - | - | -0.74 |
Stock-Based Compensation | - | - | 9.36 | - | 29.29 | 0.57 |
Provision & Write-off of Bad Debts | 0.67 | -1.64 | 5.91 | - | - | - |
Other Operating Activities | -0.79 | -4.71 | -17.11 | -10.16 | -4.83 | 4.36 |
Change in Accounts Receivable | -0.13 | -0.8 | -9.08 | -10.58 | - | - |
Change in Inventory | -2.01 | 2.7 | 8.34 | -11.72 | -0.21 | - |
Change in Accounts Payable | -0.04 | -0.08 | -0.08 | 0.29 | 11.72 | 2.83 |
Change in Unearned Revenue | 5 | 5 | - | 2.6 | 12.31 | 3.25 |
Change in Other Net Operating Assets | -3.56 | -14.69 | -2.69 | -2.52 | -1.72 | 2.84 |
Operating Cash Flow | -152.67 | -135.75 | -87.41 | -110.8 | -232.2 | -95.51 |
Capital Expenditures | -1.09 | -1.86 | -205.89 | -0.91 | -7.34 | -123.01 |
Sale (Purchase) of Intangibles | -0.59 | -0.59 | -0.24 | -0.22 | - | - |
Investment in Securities | 308.13 | 603.16 | -992.64 | -279.84 | -194.5 | -123.76 |
Other Investing Activities | 0.03 | -0.02 | 0.31 | - | -0.17 | 0.36 |
Investing Cash Flow | 306.48 | 600.68 | -1,198 | -280.97 | -202.01 | -246.42 |
Short-Term Debt Issued | - | 127.79 | 270.04 | 119.16 | 50.29 | 144.56 |
Total Debt Issued | 131.39 | 127.79 | 270.04 | 119.16 | 50.29 | 144.56 |
Short-Term Debt Repaid | - | -121.79 | -237.45 | -181.51 | -30 | -60.73 |
Long-Term Debt Repaid | - | -3.06 | -2.69 | -5.04 | -4.9 | -4.73 |
Total Debt Repaid | -124.82 | -124.85 | -240.14 | -186.55 | -34.9 | -65.46 |
Net Debt Issued (Repaid) | 6.57 | 2.95 | 29.9 | -67.39 | 15.4 | 79.11 |
Issuance of Common Stock | - | - | 1,989 | 11.95 | 575.42 | 22.66 |
Repurchase of Common Stock | -304.74 | -386.16 | -146.84 | - | - | - |
Other Financing Activities | -0.44 | -5.4 | 9.15 | 43.34 | 13.24 | 0 |
Financing Cash Flow | -298.62 | -388.61 | 1,881 | -12.1 | 604.05 | 101.77 |
Foreign Exchange Rate Adjustments | -8.48 | -0.88 | 24.31 | 5.94 | 47.55 | -12.96 |
Net Cash Flow | -153.3 | 75.43 | 619.88 | -397.92 | 217.39 | -253.11 |
Free Cash Flow | -153.76 | -137.62 | -293.3 | -111.7 | -239.54 | -218.52 |
Free Cash Flow Margin | -401.63% | -377.59% | -915.41% | -590.55% | -20956.69% | -19118.11% |
Free Cash Flow Per Share | -1.25 | -1.11 | -2.43 | -0.99 | -2.15 | -2.00 |
Cash Interest Paid | 5.04 | 5.01 | 4.3 | 7.19 | 3.07 | 1.08 |
Cash Income Tax Paid | 0.18 | 0.12 | 0.08 | 0.04 | -0.05 | -0.16 |
Levered Free Cash Flow | 66.76 | -110.53 | -316.82 | -23.45 | -255.26 | -239.95 |
Unlevered Free Cash Flow | 69.93 | -107.31 | -314.14 | -18.96 | -253.27 | -239.21 |
Change in Working Capital | -0.73 | -7.87 | -3.51 | -21.92 | 22.1 | 8.92 |